Clinical trials: Graft-vs-host Disease
Graft vs Host Disease, Mesenchymal Stem Cell Transplantation
Use of Bone Marrow Stem Cells (MesenCell) for the Treatment of Patients With Chronic Graft-versus-host Disease
The purpose of this Phase I clinical trial is to evaluate the safety and potential treatment response of bone marrow-derived mesenchymal stem cells (MesenCell) in adult patients with moderate or severe chronic graft-versus-host…
- Trial name
- NCT07826676
- Testing
- Mesenchymal Stem Cell Infusion
- Where
- 4 sites in Brazil
- Volunteers
- 20 people
- Sponsor
- Pontifícia Universidade Católica do Paraná
Graft Versus Host Disease
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
In this study the investigators are proposing to treat patients with steroid-refractory Graft-versus-host Disease (GVHD) stabilization using IL-2 and azacitidine
- Trial name
- T-REG (NCT01453140)
- Testing
- Cyclophosphamide and Sirolimus, Low dose IL-2 with Cytoxan + Sirolimus, Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Hackensack Meridian Health
Graft vs Host Disease, Hematopoietic Stem Cell Transplantation
Mycophenolate Mofetil for the Prophylaxis of Graft-versus-host Disease in High Risk Allogeneic Stem Cell Transplantation
There is a significant (50-80%) risk of acute graft-versus-host disease(GVHD) and early mortality (30%) associated with high risk stem cell transplantation (SCT) such as that from a matched unrelated donor or HLA-mismatch…
- Trial name
- NCT00563589
- Testing
- mycophenolate mofetil, methotrexate, cyclosporin, Methotrexate and cyclosporin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hospital Authority, Hong Kong
Graft Versus Host Disease
A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)
The purpose of this study is to determine the efficacy of the combination of rituximab and prednisone as initial therapy for chronic graft-versus-host disease (C-GVHD).
- Trial name
- NCT01066598
- Testing
- Rituximab
- Where
- 3 sites in Canada
- Volunteers
- 1 people
- Sponsor
- University Health Network, Toronto
Breast Neoplasms
Stem Cell Transplant With Th2/Tc2 Cells to Treat Advanced Breast Cancer
This Phase 1 trial will investigate the safety of a modified stem cell transplant procedure for treating advanced breast cancer.
- Trial name
- NCT00079625
- Testing
- Th2/Tc2 Cells
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Constipation
A Study to Evaluate the Effects of a Natural Supplement in Adults With Chronic Functional Constipation
Constipation is common in the general population, especially in women and in the elderly. Hard stool is a complaint often associated with constipation, which suggests that stool softening would provide a major benefit in the…
- Trial name
- NCT02073006
- Testing
- Natural Fibre Supplement
- Where
- Ireland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Atlantia Food Clinical Trials
AML, CML
Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant
This is a phase I inter-patient dose escalation open labeled study assessing multiple doses of CYT107 in patients of at least 15 years of age, who are recipients of HLA matched ex vivo T cell depleted bone marrow or peripheral…
- Conditions
- AML, CML, MDS
- Trial name
- NCT00684008
- Testing
- CYT107 - Recombinant glycosylated human interleukin 7., rhIL-7 (CYT107)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Cytheris, Inc.
Graft Versus Host Disease, Hematologic Neoplasms
Optimizing PTCy Dose and Timing
Background: Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient's body as foreign. This can cause complications.
- Trial name
- NCT03983850
- Testing
- Busulfan, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Graft vs Host Disease, Graft Versus Host Disease
Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT
The purpose of this study is to examine the gut bacteria, levels of peripheral blood inflammation markers, and symptoms in patients with and without chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic…
- Conditions
- Graft vs Host Disease, Graft Versus Host Disease, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation
- Trial name
- NCT02398708
- Testing
- Questionnaires, Blood Sample, Stool Sample
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Florida
Graft-Versus-Host Disease
The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease
Etanercept (Enbrel) will be added to standard therapy for acute Graft-versus-Host Disease to see if the effectiveness of standard therapy can be improved. Partial Funding Source- FDA OOPD
- Trial name
- NCT00141713
- Testing
- Etanercept
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan Rogel Cancer Center
Graft Versus Host Disease
T&B Depletion Non Malignant
The primary aim of the present trial is to assess in a randomized fashion the benefit on standard graft-versus-host disease (GVHD) prophylaxis of the addition of ATG-Fresenius S ® in transplants from matched related donors (MRD)…
- Trial name
- NCT01810926
- Testing
- polyclonal antibody, Rituximab, Treosulfan
- Where
- 4 sites in Italy
- Volunteers
- 130 people
- Sponsor
- Franco Locatelli
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow failure disorder.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00755040
- Testing
- cyclosporine ophthalmic emulsion
- Where
- 5 sites in United States
- Volunteers
- 164 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Cutaneous T Cell Lymphoma, Graft Versus Host Disease
Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment
Extracorporeal Photopheresis (ECP) is a form of apheresis and photodynamic therapy in which the peripheral blood is treated with 8-methoxypsoralen, which is then activated with UV light.
- Trial name
- NCT01460914
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Graft Versus Host Disease (GVHD)
Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone
Study CSL964_5001 will investigate the efficacy of AAT with corticosteroids compared with corticosteroids alone as first line therapy for patients with high-risk acute GVHD
- Trial name
- NCT04167514
- Testing
- Alpha-1 antitrypsin (AAT)
- Where
- 25 sites in United States
- Volunteers
- 136 people
- Sponsor
- CSL Behring
Neuropathic Pain
Oral Ketamine Administration in Patients With Peripheral Neuropathic Pain
Nowadays, available drugs cannot always produce pain relief in patients with neuropathic pain disease. It is believed that drugs acting as antagonists of the N-methyl-D-aspartic acid (NMDA) receptor may have been efficient in the…
- Trial name
- KETACLUD (NCT00961194)
- Testing
- Ketamine
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Toulouse
Bronchiolitis Obliterans Syndrome
Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of itacitinib in participants with post-lung transplant bronchiolitis obliterans syndrome (BOS).
- Trial name
- NCT03978637
- Testing
- Itacitinib
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 23 people
- Sponsor
- Incyte Corporation
Graft vs Host Disease
Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease, a Phase 1-2 Study
The purpose of this study is to evaluate safety and efficacy using decidual stromal cell therapy for graft versus host disease after allogeneic hematopoietic stem cell transplantation.
- Trial name
- NCT02172937
- Testing
- Decidual Stromal Cells thawed in plasma, Decidual Stromal Cells thawed in human albumin
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Karolinska Institutet
Hematologic Neoplasms
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies
Background: Certain blood cancers can be treated with blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called graft-versus-host disease (GVHD).
- Trial name
- NCT04959175
- Testing
- Mycophenolate Mofetil, Allogeneic HSCT, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Graft Versus Host Disease
Ocular Graft Versus Host Disease After Hematopoietic Stem Cell Transplantation in Adults
The purpose of this study is to evaluate the presence and manifestations of ocular graft versus host disease in adults that had hematopoietic stem cell transplantation in the past 3 years at the sheba medical center, Israel.
- Trial name
- NCT00912067
- Where
- Israel
- Volunteers
- 120 people
- Sponsor
- Sheba Medical Center
Hematologic Malignancies
GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease
The purpose of this study is to assess the impact and safety of itacitinib in combination with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of graft-versus-host-disease (GVHD).
- Trial name
- NCT03320642
- Testing
- Itacitinib, Calcineurin inhibitor
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 84 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.